Regional anticoagulation with acid citrate dextrose‐A for extracorporeal photoimmunochemotherapy
暂无分享,去创建一个
[1] Thomas Lang,et al. Simplified citrate anticoagulation for high-flux hemodialysis. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] R. Apsner,et al. Dalteparin-induced alopecia in hemodialysis patients: reversal by regional citrate anticoagulation. , 2001, Blood.
[3] R. Tigelaar,et al. Induction of human tumor‐loaded dendritic cells , 2001, International journal of cancer.
[4] P. Adeleine,et al. Heparins and blood polymorphonuclear stimulation in haemodialysis: an expansion of the biocompatibility concept. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[5] T. Price,et al. Frequency of immediate adverse effects associated with therapeutic apheresis , 1999, Transfusion.
[6] B. Griffith,et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. , 1998, The New England journal of medicine.
[7] H. Hönigsmann,et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. , 1998, Blood.
[8] J. van Limbeek,et al. Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis. , 1997, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[9] B. Balda,et al. Treatment of cutaneous T‐cell lymphoma with extracorporeal photochemotherapy , 1996 .
[10] W. Hörl,et al. Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation. , 1996, Journal of the American Society of Nephrology : JASN.
[11] R. Ramakrishna,et al. Heparin‐induced thrombocytopenia: cross‐reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran) , 1995, British journal of haematology.
[12] H. Hönigsmann,et al. Renal allograft rejection controlled by photopheresis , 1995, The Lancet.
[13] P. Bjerring,et al. Photopheresis and systemic sclerosis. , 1992, Archives of dermatology.
[14] J. Hirsh,et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. , 1992, Chest.
[15] F. Kerdel,et al. Pemphigus vulgaris treated with photopheresis. , 1992, Journal of the American Academy of Dermatology.
[16] F. Trautinger,et al. Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. , 1992, Arthritis and rheumatism.
[17] K Wolff,et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. , 1987, The New England journal of medicine.
[18] M. Flanigan,et al. Reducing the hemorrhagic complications of hemodialysis: a controlled comparison of low-dose heparin and citrate anticoagulation. , 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] I. Szymanski,et al. Ionized Calcium During Plateletpheresis , 1978, Transfusion.
[20] D. S. Hall,et al. REGIONAL ANTICOAGULATION DURING HEMODIALYSIS USING CITRATE , 1961, The American journal of the medical sciences.
[21] T. Greenwalt,et al. American Association of Blood Banks , 1959 .